MedPath

Physiological Effects of Non-invasive Mechanical Ventilation Versus High-flow Nasal Cannula in Critically Ill Patients At High Risk of Extubation Failure

Not Applicable
Completed
Conditions
Weaning from Mechanical Ventilation
Interventions
Device: Non-invasive ventilation (NIV)
Device: High-flow nasal cannula
Registration Number
NCT05012696
Lead Sponsor
Pontificia Universidad Catolica de Chile
Brief Summary

Weaning is one of the most complex challenges in mechanically ventilated patients. Increased work of breathing after extubation would play a central role in weaning failure. Currently, non-invasive ventilation (NIV) is recommended to prevent weaning failure in high-risk patients. On the other hand, high-flow nasal cannula (HFNC), which is a novel system capable of administering gas mixtures (air and oxygen) with a flow of up to 60 liters/min, has been used to prevent weaning failure in this kind of patients. The use of NIV and HFNC after extubation has been evaluated in some clinical studies. However, the evidence is controversial, and the information regarding the physiological effects that each therapy induces in recently extubated patients at high risk of weaning failure is lacking.

The goal of this proposal is to compare the acute physiological effects of postextubation NIV versus HFNC in critically ill patients at high risk of weaning failure on relevant mechanisms related to weaning failure: Work of breathing, lung function, ventilation distribution, systemic hemodynamics.

This will be a randomized crossover study that will include critically ill mechanically ventilated patients, who fulfill criteria indicating they may be ready for weaning from mechanical ventilation, and in whom a spontaneous breathing trial (SBT) is planned to determine if they should be extubated. After checking eligibility and obtaining informed consent, patients will be monitored with an esophageal catheter (esophageal/gastric pressures to determine work of breathing, and electric activity of diaphragm to determine neuromechanical coupling), and a noninvasive ventilation monitor (electric impedance tomography to assess global and regional ventilation). Work of breathing, lung function, and systemic hemodynamics will be assessed during the SBT. Inclusion in the study will be confirmed only if they pass the SBT and are extubated. During the first 2 hours after extubation, patients will undergo one hour of NIV and one hour of HFNC, with the crossover sequence being randomized previously at the time of inclusion and with assessments repeated at the end of each treatment period.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  1. Mechanical ventilation (MV) through an orotracheal tube for at least 48 hours

  2. PaO2 /FiO2 ratio ≤ 300 mmHg (during the MV period)

  3. Potential for weaning

    • Precipitating cause leading to MV in resolution
    • PaO2 /FiO2 ratio ≥ 150 mmHg
    • PEEP ≤ 8 cmH2O
    • pH > 7,25
    • SpO2 ≥ 90% with FiO2 ≤ 0.4; BPM ≤35
    • Hemodynamic stability (noradrenaline ≤ 0.1mcg / kg / min and SBP 90-160; HR <140)
    • Temperature <38 ° C
    • Presence of inspiratory effort and appropriate spontaneous cough
    • Decision to perform a spontaneous breathing trial by the attending physician
  4. High risk of weaning failure defined by a history of: (i) Previous failed extubation, (ii) Chronic heart or respiratory failure, or (iii) MV ≥ 7 days.

Exclusion Criteria
  1. Contraindications to NIV or HFNC, which include abnormalities, trauma or surgery of the face or nose.
  2. Contraindications for esophageal balloon catheter insertion (eg. severe coagulopathy, esophageal varices, and history of esophageal or gastric surgery)
  3. Contraindication for use of electric impedance tomography (eg. Pacemaker)
  4. Tracheostomy
  5. Refusal to participate by the attending physician
  6. Do not resuscitate order

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Sequence A: Non-invasive ventilation - High flow nasal cannulaNon-invasive ventilation (NIV)Once participants are extubated they will receive one hour of Non-invasive ventilation followed by one hour of high-flow nasal cannula.
Sequence A: Non-invasive ventilation - High flow nasal cannulaHigh-flow nasal cannulaOnce participants are extubated they will receive one hour of Non-invasive ventilation followed by one hour of high-flow nasal cannula.
Sequence B: High flow nasal cannula - Non-invasive ventilationHigh-flow nasal cannulaOnce participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of Non-invasive ventilation
Sequence B: High flow nasal cannula - Non-invasive ventilationNon-invasive ventilation (NIV)Once participants are extubated they will receive one hour of high flow nasal cannula followed by one hour of Non-invasive ventilation
Primary Outcome Measures
NameTimeMethod
Pressure time-product (PTP) per minute60 minutes after starting Non-invasive ventilation or high flow nasal cannula

Pressure time-product (PTP) per minute (cmH2O x s/min)

Esophageal pressure swings (ΔPes)60 minutes after starting Non-invasive ventilation or high flow nasal cannula

Esophageal pressure swings (ΔPes) defined as the absolute differences between end-expiratory and end-inspiratory Pes

End-expiratory lung impedance (EELI)60 minutes after starting Non-invasive ventilation or high flow nasal cannula

End-expiratory lung impedance (EELI)assessed with Electric impedance tomography

Secondary Outcome Measures
NameTimeMethod
Pressure time-product per breath60 minutes after starting Non-invasive ventilation or high flow nasal cannula

Pressure time-product per breath (cmH2O x s). PTP will be assessed through an esophageal Neurovent catheter.

Peak electric activity of the diaphragm (EAdi)60 minutes after starting Non-invasive ventilation or high flow nasal cannula

Peak electric activity of the diaphragm (EAdi) EAdi will be measured in uV through a Neurovent catheter connected to a Servo-i ventilator

Neuroventilatory efficiency60 minutes after starting Non-invasive ventilation or high flow nasal cannula

Neuroventilatory efficiency is a parameter derived from the EAdi signal and the ventilation

Diaphragmatic neuromuscular coupling60 minutes after starting Non-invasive ventilation or high flow nasal cannula

Diaphragmatic neuromuscular coupling Pdi/EAdi

Global inhomogeneity index60 minutes after starting Non-invasive ventilation or high flow nasal cannula ]

Index derived from EIT and calculated from the sum of the impedance changes of each pixel with respect to its median (in absolute values), divided by the sum of the impedance values of each pixel

PaO2 / FiO2 ratio60 minutes after starting Non-invasive ventilation or high flow nasal cannula

Parameter of oxygen exchange calculated as the ratio of PaO2 / FiO2

PaCO260 minutes after starting Non-invasive ventilation or high flow nasal cannula

Arterial partial pressure of CO2 (PaCO2) Parameter of alveolar ventilation

Trial Locations

Locations (1)

Hospital Clínico UC Christus

🇨🇱

Santiago, Region Metropolitana, Chile

© Copyright 2025. All Rights Reserved by MedPath